Source comparison
BPC-157 Inflammation Research: Model Comparison
Tendon/Ligament Injury IL-1β, TNF-α, MMP-9 40–65% faster tensile strength recovery; increased collagen organization; reduced scar tissue formation 10 μg/kg daily (systemic) 7–14 days Effect size diminishes in chronic (>8 week) injuries Gastric Ulceration TNF-α
This comparison does not assign a generated winner or score.
- Tendon/Ligament Injury
- IL-1β, TNF-α, MMP-9
- 40–65% faster tensile strength recovery; increased collagen organization; reduced scar tissue formation
- 10 μg/kg daily (systemic)
- 7–14 days
- Effect size diminishes in chronic (>8 week) injuries
- Gastric Ulceration
- TNF-α, IL-6, iNOS, ROS
- 70–85% reduction in ulcer area; maintained mucosal blood flow; prevented NSAID-induced damage
- 10 μg/kg daily (systemic) or 1 μg topical
- 3–7 days
- Requires concurrent removal of ulcerogenic stimulus
- Inflammatory Bowel Disease
- TNF-α, IL-1β, MPO, leukotrienes
- 60–75% reduction in disease activity index; decreased MPO activity; improved epithelial barrier function
- 5–10 days
- Model-dependent variability; effect strongest in acute colitis models
- Muscle Injury (Contusion/Strain)
- IL-6, CK, LDH, oxidative stress markers
- 50–60% faster functional recovery; reduced creatine kinase elevation; accelerated regeneration of myofibers
- 4–7 days
- Less effective in severe crush injuries with extensive necrosis
- Vascular Injury/Anastomosis
- VEGF, NO, endothelial adhesion molecules
- Maintained blood flow during NOS inhibition; prevented thrombosis; accelerated endothelial healing
- Requires intact vascular endothelium for optimal effect